Clinical Trials Logo

Filter by:
NCT ID: NCT05552976 Recruiting - Clinical trials for Relapsed or Refractory Multiple Myeloma

A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)

SUCCESSOR-2
Start date: January 10, 2023
Phase: Phase 3
Study type: Interventional

The purpose of the study is to compare Mezigdomide (CC-92480/BMS-986348) with carfilzomib and dexamethasone (MeziKD) against carfilzomib and dexamethasone (Kd) in the treatment of RRMM: SUCCESSOR-2.

NCT ID: NCT05552963 Active, not recruiting - Clinical trials for Refractory Paroxysmal Atrial Fibrillation

A Study of Multi-electrode Circular Irreversible Electroporation (IRE) Catheter and Multi-Channel IRE Generator in Paroxysmal Atrial Fibrillation (AF)

AFIRE
Start date: December 7, 2022
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the long term off-Antiarrhythmic Drug (AAD) effectiveness of Biosense Webster, Inc. Irreversible Electroporation (BWI IRE) system in treatment of participants with symptomatic drug refractory paroxysmal atrial fibrillation (PAF).

NCT ID: NCT05552937 Recruiting - DLBCL Clinical Trials

Evaluate the Safety and Efficacy of Tafasitamab Combined With Lenalidomide in Patients With Relapsed or Refractory DLBCL

Start date: September 6, 2021
Phase: Phase 2
Study type: Interventional

This is a A Phase II, Single-Arm, Open-Label, Multicentre Study to Evaluate the Safety and Efficacy of Tafasitamab Combined with Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

NCT ID: NCT05552911 Recruiting - Clinical trials for Coronary Heart Disease

Drug-coated Balloon Therapy for In-stent Restenosis and de Novo Coronary Lesions

Start date: January 1, 2022
Phase:
Study type: Observational

This was a single-center, prospective, open-label, observational study. Patients with coronary artery disease confirmed by coronary angiography and treated with drug-coated balloon catheter alone for target vessels were enrolled in the Cardiology Department of our hospital in January 2022. The primary endpoint was late lumen loss within 12±3 months after surgery.

NCT ID: NCT05552872 Recruiting - Diabetes Mellitus Clinical Trials

Study on Diagnosis Value of mNGS Technology Among Diabetic Patients With Pulmonary Infections

Start date: September 1, 2022
Phase:
Study type: Observational [Patient Registry]

Focusing on patients with diabetes complicated with pulmonary infection, the purpose of this study is: 1) to identify the epidemiology, etiologic spectrum and status of diagnosis and treatment; 2) to explore the lower respiratory microenvironment and host immune response and then make an application in clinic.

NCT ID: NCT05552846 Recruiting - Clinical trials for Small-cell Lung Cancer

Phase II Trial of Consolidative Thoracic Radiotherapy for ES-SCLC After Standard Care of Chemo-immunotherapy

Start date: September 30, 2022
Phase: Phase 2
Study type: Interventional

This is an open-label, single arm Phase II study designed to evaluate the efficacy and safety of thoracic radiotherapy for extensive-stage small-cell lung cancer treated with PD-1/PD-L1 plus etoposide platinum followed by PD-1/PD-L1 maintenance therapy

NCT ID: NCT05552820 Recruiting - Dry Eye Clinical Trials

Electroacupuncture for Mild-to-moderate Dry Eye

Start date: October 12, 2022
Phase: N/A
Study type: Interventional

To determine if electroacupuncture acts as an dry eye treatment rather than a placebo, and identify if benefits are linked to corneal subbasal nerve changes and neuroimmunomodulatory indicators.

NCT ID: NCT05552807 Recruiting - Clinical trials for Head and Neck Squamous Carcinoma

SCT200 in Combination With SCT-I10A/Paclitaxel/Docetaxel in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Start date: June 15, 2022
Phase: Phase 1
Study type: Interventional

The study is to explore the efficacy and safety of SCT200 with SCT-I10A or SCT200 combined with paclitaxel/docetaxel in the treatment of recurrent/metastatic head and neck squamous cell carcinoma.

NCT ID: NCT05552781 Recruiting - Clinical trials for Non-small Cell Lung Cancer

H002 in Patients With EGFR Mutation Locally Advanced or Metastatic NSCLC

Start date: August 26, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a phase I/IIa, open-label, dose-escalation and expansion study to evaluate the safety, tolerability, PK and preliminary anti-tumor activity of H002 when given orally in patients with EGFR mutation-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). The study will contain two parts: Part A is dose escalation phase (i.e., Phase I) and Part B is dose expansion phase (i.e., Phase IIa).

NCT ID: NCT05552729 Not yet recruiting - Clinical trials for Cognitive Impairment

Effects of Different Doses of Vitamin D on Cancer-related Cognitive Impairment in Patients With Gastrointestinal Tumors

Start date: September 22, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

To explore the effect of different doses of vitamin D drugs on gastrointestinal cancer cancer-related cognitive impairment, so as to provide reference and basis for the clinical use of our cognitive function surgery nursing plan for patients with gastrointestinal cancer.